Pipeline &
Science
Science is the foundation of everything we do.
In our quest to bring hope to those living with neurodegenerative diseases and neurodevelopmental disorders, we continuously advance our knowledge and understanding of pridopidine’s mechanism of action. With expertise and determination, we partner with leading labs and clinicians across the globe to discover novel therapeutic approaches.
Pipeline
The need continues, so the research continues. Our pipeline and clinical studies represent research into indications for pridopidine, our first-in-class, investigational selective sigma-1 receptor (S1R) agonist.
Pipeline
The need continues, so the research continues. Our pipeline and clinical studies represent research into indications for pridopidine, our first-in-class, investigational selective sigma-1 receptor (S1R) agonist.
About Pridopidine
Pridopidine is a first-in-class, investigational oral therapy. In clinical studies, pridopidine has been well-tolerated with a safety profile comparable to placebo. At the therapeutic dose, pridopidine activates the S1R in a highly selective manner, leading to enhanced neuroprotection across neurodegenerative diseases, such as Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and neurodevelopmental disorders.
About Pridopidine
Pridopidine is a first-in-class, investigational oral therapy. In clinical studies, pridopidine has been well-tolerated with a safety profile comparable to placebo. At the therapeutic dose, pridopidine activates the S1R in a highly selective manner, leading to enhanced neuroprotection across neurodegenerative diseases, such as Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and neurodevelopmental disorders.
Publications
Peer-reviewed publications about pridopidine.
Publications
Peer-reviewed publications about pridopidine.
Pridopidine is an investigational product and has not been approved by the U.S. Food & Drug Administration or other ex-US regulatory agencies. Its safety and efficacy have not yet been determined.